XML 29 R21.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Reporting
 3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Segment Reporting

12. Segment Reporting

All revenues for the three months ended March 31, 2025 and 2024 were generated from customers in the North America. The following table illustrates reported segment revenue, segment profit and significant segment expenses (in thousands):

 

 

Three Months Ended March 31,

 

 

 

2025

 

 

2024

 

NUPLAZID net revenue

 

$

159,721

 

 

$

129,923

 

DAYBUE net revenue

 

 

84,596

 

 

 

75,908

 

Total revenues

 

 

244,317

 

 

 

205,831

 

Less:

 

 

 

 

 

 

Cost of goods sold

 

 

9,211

 

 

 

10,074

 

License fees and royalties

 

 

11,181

 

 

 

12,877

 

Research and development expense:

 

 

 

 

 

 

External research and development

 

 

54,985

 

 

 

41,489

 

Internal costs(1)

 

 

23,280

 

 

 

18,190

 

Total research and development expense

 

 

78,265

 

 

 

59,679

 

Selling, general and administrative

 

 

126,370

 

 

 

107,991

 

Interest income, net

 

 

(7,901

)

 

 

(5,506

)

Other income

 

 

(588

)

 

 

(286

)

Income tax expense

 

 

8,792

 

 

 

4,447

 

Consolidated net income

 

$

18,987

 

 

$

16,555

 

_______________

(1)
Includes personnel expenses and costs allocated to multiple research and development programs, including benefits, information technology, facilities and inventory.